NASDAQ:CKPT

Checkpoint Therapeutics - CKPT Stock Forecast, Price & News

$0.98

-0.08 (-7.53%)

(As of 09/26/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.97
▼
$1.06
50-Day Range: $1.05
▼
$1.47
52-Week Range: $0.96
▼
$4.64

Volume: 429,915 shs
Average Volume: 835,763 shs
Market Capitalization: $90.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.50

Checkpoint Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,925.4% Upside
$19.75 Price Target
Short Interest: Healthy
3.55% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.63
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.71) to ($0.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

836th out of 1,069 stocks

Pharmaceutical Preparations Industry

399th out of 533 stocks

3.5

Analyst's Opinion

Consensus Rating
Checkpoint Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.75, Checkpoint Therapeutics has a forecasted upside of 1,925.4% from its current price of $0.98.
Amount of Analyst Coverage
Checkpoint Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.55% of the outstanding shares of Checkpoint Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Checkpoint Therapeutics has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in Checkpoint Therapeutics has recently decreased by 0.30%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Checkpoint Therapeutics does not currently pay a dividend.
Dividend Growth
Checkpoint Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Checkpoint Therapeutics has received a 62.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Checkpoint Therapeutics is -0.63.

0.0

News and Social Media Coverage

Search Interest
Only 3 people have searched for CKPT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Checkpoint Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Checkpoint Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Checkpoint Therapeutics is held by insiders.
Percentage Held by Institutions
Only 10.79% of the stock of Checkpoint Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Checkpoint Therapeutics are expected to decrease in the coming year, from ($0.71) to ($0.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Checkpoint Therapeutics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Checkpoint Therapeutics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Checkpoint Therapeutics has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Checkpoint Therapeutics (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CKPT Stock News Headlines

September 17, 2022 | nasdaq.com

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

September 8, 2022 | seekingalpha.com

Checkpoint: Strong Data, But Comes With Risks

September 7, 2022 | bizjournals.com

Checkpoint Surgical names new CEO as founder Len Cosentino steps aside

August 26, 2022 | msn.com

Burbank Police to Set Up DUI Checkpoint on Saturday Night

August 16, 2022 | bizjournals.com

Waltham biotech Checkpoint Therapeutics stops cancer study due to Ukraine war

August 12, 2022 | marketwatch.com

Checkpoint Swings to 2Q Loss, Ends Trial Due to War in Ukraine

August 9, 2022 | marketwatch.com

Immune Checkpoint Inhibitors Market Trends 2022 Sales, Top Vendors, Growth Insights, Segments, Size, Industry Share and Forecast to 2029

July 19, 2022 | marketwatch.com

Global Immune Checkpoint Inhibitors Market 2022 Opportunity Analysis, Comprehensive Insights, CAGR Status and Future Opportunity Assessment by 2028

July 8, 2022 | marketwatch.com

Checkpoint Inhibitors for Treating Cancer Market Size, Status, Top Players, Trends and Forecast to 2025

July 7, 2022 | msn.com

Truck crashes into multiple vehicles on Causeway near Woodlands Checkpoint

June 30, 2022 | finance.yahoo.com

We're Keeping An Eye On Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

June 17, 2022 | markets.businessinsider.com

Checkpoint set to present its latest technologies at NRF Protect 2022

June 16, 2022 | msn.com

Checkpoint' Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer Patients

June 16, 2022 | seekingalpha.com

Checkpoint Therapeutics trial generates positive interim results for skin cancer candidate

June 16, 2022 | nasdaq.com

Checkpoint Reports Positive Interim Efficacy Results From Trial Evaluating Cosibelimab

June 16, 2022 | marketwatch.com

Checkpoint Therapeutics Shares Rise Premarket on Positive Study >CKPT

May 14, 2022 | seekingalpha.com

Checkpoint Therapeutics GAAP EPS of -$0.20

May 13, 2022 | seekingalpha.com

Checkpoint gains as H.C. Wainwright cheers key regulatory milestone in Europe

May 13, 2022 | finance.yahoo.com

Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

May 4, 2022 | msn.com

Novato PD To Hold DUI Checkpoint

May 4, 2022 | msn.com

All Stormtrooper Checkpoint locations in Fortnite

April 27, 2022 | msn.com

DUI Checkpoint Scheduled This Weekend In Wildomar

March 31, 2022 | finance.yahoo.com

Here's What Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shareholder Ownership Structure Looks Like

March 29, 2022 | benzinga.com

Checkpoint Therapeutics's Return On Capital Employed Insights

March 28, 2022 | finance.yahoo.com

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CKPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CKPT Company Calendar

Last Earnings: 8/12/2022
Today: 9/26/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CKPT
CUSIP: N/A
CIK: 1651407
Web: www.checkpointtx.com
Phone: (781) 652-4500
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $19.75
High Stock Price Forecast: $26.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +1,273.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-56,670,000.00
Net Margins: -62,618.26%
Pretax Margin: -62,618.26%
Return on Equity: -273.30%
Return on Assets: -150.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.30
Quick Ratio: 1.30

Sales & Book Value

Annual Sales: $270,000.00
Price / Sales: 336.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.34 per share
Price / Book: 2.89

Miscellaneous

Outstanding Shares: 92,497,000
Free Float: 87,780,000
Market Cap: $90.91 million
Optionable: Not Optionable
Beta: 1.66

Key Executives

Mr. James F. Oliviero III (Age 46)
C.F.A., CFA, Pres, CEO & Director
Comp: $874.8k

Mr. William Garrett Gray (Age 35)
CFO, Corp. Sec. & Treasurer
Comp: $350.94k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CKPT Stock - Frequently Asked Questions

Should I buy or sell Checkpoint Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CKPT shares.
View CKPT analyst ratings or view top-rated stocks.
What is Checkpoint Therapeutics' stock price forecast for 2022?: 2 Wall Street analysts have issued 12 month price targets for Checkpoint Therapeutics' shares. Their CKPT share price forecasts range from $7.00 to $26.00. On average, they anticipate the company's stock price to reach $19.75 in the next year. This suggests a possible upside of 1,763.2% from the stock's current price.
View analysts price targets for CKPT or view top-rated stocks among Wall Street analysts.
How have CKPT shares performed in 2022?: Checkpoint Therapeutics' stock was trading at $3.11 at the beginning of 2022. Since then, CKPT shares have decreased by 65.9% and is now trading at $1.06.
View the best growth stocks for 2022 here.
When is Checkpoint Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CKPT earnings forecast.
How were Checkpoint Therapeutics' earnings last quarter?: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) posted its quarterly earnings results on Friday, August, 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.07 million. Checkpoint Therapeutics had a negative trailing twelve-month return on equity of 273.30% and a negative net margin of 62,618.26%.

What other stocks do shareholders of Checkpoint Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Kadmon (KDMN) and Rigel Pharmaceuticals (RIGL).
What is Checkpoint Therapeutics' stock symbol?: Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."
Who are Checkpoint Therapeutics' major shareholders?: Checkpoint Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Morgan Jess S & Co. Inc. (1.25%), Millennium Management LLC (0.92%), Renaissance Technologies LLC (0.83%), Park Avenue Securities LLC (0.12%), Apollon Wealth Management LLC (0.11%) and Virtu Financial LLC (0.05%). Insiders that own company stock include James F Oliviero III, Lindsay A Md Rosenwald and William Garrett Gray.
View institutional ownership trends.
How do I buy shares of Checkpoint Therapeutics?: Shares of CKPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Checkpoint Therapeutics' stock price today?: One share of CKPT stock can currently be purchased for approximately $1.06.
How much money does Checkpoint Therapeutics make?: Checkpoint Therapeutics (NASDAQ:CKPT) has a market capitalization of $98.05 million and generates $270,000.00 in revenue each year. The company earns $-56,670,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.
How can I contact Checkpoint Therapeutics?: Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.checkpointtx.com. The company can be reached via phone at (781) 652-4500 or via email at investor@chimerareit.com.

This page (NASDAQ:CKPT) was last updated on 9/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Checkpoint Therapeutics - CKPT Stock Forecast, Price & News

Checkpoint Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month